Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension

Rhodes, Christopher J.; Wharton, John; Boon, Reinier A.; Roexe, Tino; Tsang, Hon Ki; Wójciak-Stothard, Beata; Chakrabarti, Anob M.; Howard, Luke; Gibbs, J. Simon R.; Lawrie, Allan; Condliffe, Robin; Elliot, Charles; Kiely, David G.; Huson, Les; Ghofrani, Hossein Ardeschir; Tiede, Henning; Schermuly, Ralph Theo; Zeiher, Andreas M.; Dimmeler, Stefanie; Wilkins, Martin R.

doi:10.1164/rccm.201205-0839oc

Cited by 158 publications

(123 citation statements)

References 38 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…A growing body of literature supports the concept that irregularities in microRNA activity and related networks promote PAH pathophysiology, which creates exciting opportunities for precision therapeutics design (19,(41)(42)(43)(44). Rhodes and colleagues analyzed pulmonary artery endothelial cells from control subjects and subjects with IPAH, using RNA sequencing to determine novel pathways perturbed in relation to reduced BMPR2 signaling (45).…”

Section: Pah and The Concept Of Precision Medicinementioning

confidence: 99%

Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing

Austin¹,

West

Loyd

et al. 2017

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Section: Pah and The Concept Of Precision Medicinementioning

confidence: 99%

Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing

Austin¹,

West

Loyd

et al. 2017

Am J Respir Crit Care Med

View full text Add to dashboard Cite

“…Several of these miR provide mechanistic insight [14] and prognostic utility [15] but discordance between models and clinical samples have reported [16].…”

Section: Editorialmentioning

confidence: 99%

miRNA-140-5p: New Avenue for Pulmonary Arterial Hypertension Drug Development?

2016

Self Cite

View full text Add to dashboard Cite

“…Rhodes et al also showed, more specifically, that downregulation of microRNA-150 is associated with a reduced 2-year survival in patients with established PAH. 49 There currently is no data available in the specific population of patients with PAH-CHD and if the micro-RNA profile differs between reversible and irreversible PAH, although microRNAs are potentially a very interesting area of research in terms of circulating biomarkers.…”

Section: Myers Po Et Almentioning

confidence: 99%

Assessment of Operability of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease

Myers

Tissot

Beghetti

2014

Circ J

View full text Add to dashboard Cite

4MYERS PO et al. Circulation JournalOfficial Journal of the Japanese Circulation Society http://www. j-circ.or.jp dvances in cardiac care have allowed the repair of congenital heart defects (CHD) in the neonatal period or in infancy for most patients, before the development of pulmonary arterial hypertension (PAH) and pulmonary vascular disease (PVD) from pulmonary overcirculation. Nonetheless, PAH associated with CHD remains a problem, mainly in patients in whom the left-to-right shunt wasn't diagnosed until childhood or even adulthood, or in patients who didn't have access to cardiovascular care and surgical management as infants, particularly in developing countries. 1 The current definition of PAH relies on a pulmonary arterial pressure ≥25 mmHg at rest, a left atrial pressure ≤15 mmHg, and normal resting cardiac output, suggesting a resting pulmonary vascular resistance of ≥3 Woods units. 2,3 The 2009 European Society of Cardiology (ESC)/European Respiratory Society (ERS)/Internation Society of Heart and Lung Transplantation (ISHLT) guidelines on the management of PAH subdivided PAH-CHD into 4 clinical groups: (1) Eisenmenger syndrome; (2) PAH associated with systemic-to-pulmonary shunts; (3) PAH with small defects; and (4) PAH after surgical repair. 3 PAH and pulmonary vascular lesions are thought to be reversed after surgery in some patients when operated on early in life. In others, PAH is thought to be irreversible and the prognosis is often worse than without surgery. 4 Patients with persistent or recurrent PAH after surgery have been shown to have worse outcomes than either those with unoperated CHD and PAH or with Eisenmenger's syndrome in a single-center retrospective review. 5 PAH in CHD is also an increasing problem, with an increasing number and proportion of patients with CHD reported in PAH registries both in adults and children. For example, in the Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP) registry, CHD patients represent 40% of included patients, 35% of which previously had surgical repair. 6 With improvement in pulmonary vasodilators and their more widespread use, it has been possible to reduce pulmonary vascular resistance (PVR) and symptoms in a subset of patient with PAH, and make these patients amenable to surgery. 1 However, most of the results provide only short-term outcomes and immediate post-operative survival does not always translate into long-term success. Given this shifting paradigm, this review focuses on how to assess operability and how novel pulmonary vasodilators are changing the management of PAH in CHD and opening new research prospects. Literature Search StrategyRigorous electronic and manual literature searches were conducted to identify reports of PAH in CHD, their assessment, operability and treatment. Articles were identified in electronic database searches of Medline, Embase and the Cochrane Library, using a predetermined search strategy including the Pulmonary arterial hypertension (PAH) is a common complication of congenital h...

show abstract

Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension

Abstract: Reduced circulating miR-150 levels are associated with poor survival in PAH.

Cited by 158 publications

References 38 publications

Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing

Translational Advances in the Field of Pulmonary Hypertension Molecular Medicine of Pulmonary Arterial Hypertension. From Population Genetics to Precision Medicine and Gene Editing

miRNA-140-5p: New Avenue for Pulmonary Arterial Hypertension Drug Development?

Assessment of Operability of Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease

Contact Info

Product

Resources

About